Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic
  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Surmodics Reports Fourth Quarter and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Financial Guidance

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its fourth quarter and fiscal year ended September 30, 2023, and introduced its financial guidance for the fiscal year ending September 30, 2024.

Fourth Quarter Fiscal 2023 Financial Summary

  • Total Revenue of $28.0 million, an increase of 8% year-over-year
  • Total Revenue excluding SurVeil™ DCB license fee revenue(1) of $26.9 million, an increase of 12% year-over-year
  • GAAP Diluted EPS of $0.47, compared to $(1.06) in the prior-year period
  • Non-GAAP Diluted EPS of $0.53, compared to $(0.26) in the prior-year period

Fiscal Year 2023 Financial Summary

  • Total Revenue of $132.6 million, an increase of 33% year-over-year
  • Total Revenue excluding SurVeil DCB license fee revenue(1) of $103.0 million, an increase of 9% year-over-year
  • GAAP Diluted EPS of $(0.11), compared to $(1.96) in the prior-year period
  • Non-GAAP Diluted EPS of $0.16, compared to $(0.95) in the prior-year period

Fourth Quarter and Recent Business Highlights

  • On October 31, 2023, Surmodics announced the launch of its Preside™ medical device coating technology providing industry-leading lubricity and durability to a broader range of complex device applications.
  • On November 7, 2023, Surmodics announced that 24-month data from its SWING first-in-human study of the company’s Sundance™ Sirolimus DCB will be presented at the Symposium on Vascular and Endovascular Issues (“VEITHsymposium”) in New York, NY on November 15, 2023.
  • On November 7, 2023, Surmodics announced that 36-month data from its TRANSCEND clinical trial of the company’s SurVeil DCB will be presented at the VEITHsymposium in New York, NY on November 15, 2023.

“We are pleased with our revenue performance in the fourth quarter, which increased 8% year-over-year – 12% excluding SurVeil DCB license fees(1) – and ultimately exceeded our guidance range, driven by impressive contributions from both of our business segments,” said Gary Maharaj, President and CEO of Surmodics, Inc. “We complemented our fourth quarter revenue performance with notable operating results, delivering positive Adjusted EBITDA and generating cash flow from operations. In addition to our financial accomplishments, we also made strong progress with respect to each of our key strategic objectives: supporting the future commercialization of our SurVeil DCB, advancing the initial commercialization of our Pounce™ arterial thrombectomy and Sublime™ radial access platforms, and driving strong revenue growth and cash flow from our ‘core’ medical device performance coatings and In Vitro Diagnostics businesses on a combined basis.”

Mr. Maharaj continued, “Looking back on fiscal 2023, our team successfully navigated multiple challenges, while ultimately achieving our stated objectives and delivering solid financial performance. We believe we are strategically positioned for future success as a result, with a portfolio and pipeline of key product growth catalysts, durable and profitable ‘core’ businesses, more than $45 million of cash and investments to support our operations, and access to approximately $61 million in available debt capital to provide additional financial flexibility. In fiscal 2024, we are committed to executing on our growth strategy efficiently to maintain a healthy balance sheet while positioning Surmodics for strong, sustainable, long-term growth and value creation.”

Fourth Quarter Fiscal 2023 Financial Results

 

 

Three Months Ended

September 30,

 

Increase

 

2023

 

2022

 

$

 

%

Revenue:

 

 

 

 

 

 

 

 

 

 

 

Medical Device

$

21,044

 

 

$

19,500

 

 

$

1,544

 

 

 

8

%

In Vitro Diagnostics

 

6,926

 

 

 

6,488

 

 

 

438

 

 

 

7

%

Total revenue

$

27,970

 

 

$

25,988

 

 

$

1,982

 

 

 

8

%

 

Total revenue increased $2.0 million, or 8%, to $28.0 million, compared to $26.0 million in the fourth quarter of fiscal 2022. Excluding SurVeil DCB license fee revenue,(1) total revenue increased $3.0 million, or 12%, to $26.9 million, compared to $23.9 million in the fourth quarter of fiscal 2022.

Medical Device revenue increased $1.5 million, or 8%, to $21.0 million, compared to $19.5 million in the fourth quarter of fiscal 2022. Excluding SurVeil DCB license fee revenue,(1) Medical Device revenue increased $2.5 million, or 15% to $20.0 million, compared to $17.4 million in the fourth quarter of fiscal 2022. Medical Device revenue growth was primarily driven by increased performance coating royalties and significant contributions to product sales from the Pounce thrombectomy device platform, partly offset by a decrease in proprietary specialty catheter product sales due to the completion of a customer development program. IVD revenue increased $0.4 million, or 7%, to $6.9 million, compared to $6.5 million in the fourth quarter of fiscal 2022, driven primarily by strong customer demand for microarray slide/surface products, as well as favorable order timing for distributed antigen products.

Product gross profit (defined as product sales less product costs) decreased $0.5 million, or 5%, to $8.3 million, compared to $8.8 million in the fourth quarter of fiscal 2022. Product gross margin (defined as product gross profit as a percentage of product sales) was 54.2%, compared to 61.1% in the fourth quarter of fiscal 2022. The decrease in product gross margin was primarily driven by the adverse mix impact from increased device product sales, which have lower product gross margins from under-absorption and production inefficiencies, including expiration of inventory, associated with low production volumes during the scale-up phase following initial commercialization.

Operating costs and expenses, excluding product costs, decreased $3.6 million, or 13%, to $23.4 million, compared to $27.0 million in the fourth quarter of fiscal 2022. The decrease was driven by lower research and development and selling, general and administrative expenses primarily as the result of the spending reduction plan implemented in the second quarter of fiscal 2023, as well as by delayed timing of certain investments in product development.

GAAP net income was $6.7 million, or $0.47 per diluted share, compared to GAAP net loss of $(14.7) million, or $(1.06) per diluted share in the fourth quarter of fiscal 2022. Non-GAAP net income was $7.5 million, or $0.53 per diluted share, compared to Non-GAAP net loss of $(3.7) million, or $(0.26) per diluted share in the fourth quarter of fiscal 2022.

Adjusted EBITDA was $1.7 million, compared to Adjusted EBITDA loss of $(2.5) million in the fourth quarter of fiscal 2022.

Fiscal Year 2023 Financial Results

 

 

Fiscal Year Ended

September 30,

 

Increase (Decrease)

 

2023

 

2022

 

$

 

%

Revenue:

 

 

 

 

 

 

 

 

 

 

 

Medical Device

$

105,783

 

 

$

72,389

 

 

$

33,394

 

 

 

46

%

In Vitro Diagnostics

 

26,801

 

 

 

27,562

 

 

 

(761

)

 

 

(3

)%

Total revenue

$

132,584

 

 

$

99,951

 

 

$

32,633

 

 

 

33

%

 

Total revenue increased $32.6 million, or 33%, to $132.6 million, compared to $100.0 million in fiscal 2022. Excluding SurVeil DCB license fee revenue,(1) total revenue increased $8.7 million, or 9%, to $103.0 million, compared to $94.3 million in fiscal 2022.

Medical Device revenue increased $33.4 million, or 46%, to $105.8 million, compared to $72.4 million in fiscal 2022. Excluding SurVeil DCB license fee revenue,(1) Medical Device revenue increased $9.5 million, or 14% to $76.2 million, compared to $66.7 million in fiscal 2022. Medical Device revenue growth was broad-based across product sales, royalties and license fees, and research and development services. Medical Device product sales growth of 22% year-over-year was driven by increased sales of the Pounce thrombectomy and Sublime radial access platforms, performance coating reagents, and contract-manufactured balloon catheters, partly offset by decreased sales of proprietary specialty catheters due to the completion of a customer development program. IVD revenue decreased $0.8 million, or 3%, to $26.8 million, compared to $27.6 million in fiscal 2022, driven primarily by lower research and development and other revenue due to the completion of a customer development program, as well as by the impact to product sales of active management of inventory levels by certain customers.

GAAP net loss was $(1.5) million, or $(0.11) per diluted share, compared to GAAP net loss of $(27.3) million, or $(1.96) per diluted share in fiscal 2022. Non-GAAP net income was $2.2 million, or $0.16 per diluted share, compared to Non-GAAP net loss of $(13.2) million, or $(0.95) per diluted share in fiscal 2022.

Adjusted EBITDA was $21.5 million, compared to Adjusted EBITDA loss of $(5.8) million in fiscal 2022.

Balance Sheet Summary

As of September 30, 2023, Surmodics reported $45.4 million in cash and investments, $5.0 million in outstanding borrowings on its revolving credit facility, and $25.0 million in outstanding borrowings on its term loan facility. The company had access to approximately $61.0 million in additional debt capital as of September 30, 2023 under its revolving credit and term loan facilities. Surmodics reported $1.3 million of cash provided by operating activities and $0.7 million in capital expenditures in the fourth quarter of fiscal 2023.

Fiscal Year 2024 Financial Guidance

Surmodics expects fiscal 2024 total revenue to range from $116 million to $121 million, representing a decrease of (13)% to (9)% compared to fiscal 2023. Excluding SurVeil DCB license fee revenue,(1) Surmodics expects fiscal 2024 total revenue to range from $112 million to $117 million, representing an increase of 9% to 14% compared to fiscal 2023.

The company expects fiscal 2024 GAAP diluted loss per share to range from $(1.55) to $(1.20). Non-GAAP diluted loss per share in fiscal 2024 is expected to range from $(1.32) to $(0.97).

Conference Call Today at 7:00 a.m. CT (8:00 a.m. ET)

Surmodics is hosting a live webcast at 7:00 a.m. CT (8:00 a.m. ET) today to discuss fourth quarter and fiscal 2023 financial results and accomplishments, and to host a question-and-answer session. To access the webcast, please go to “Events & Presentations” under the “Investors” section of the company’s website at https://surmodics.gcs-web.com/events-and-presentations, and click on the webcast icon under “Upcoming Events.” To listen to the live teleconference, dial 800-267-6316 (international callers may dial 203-518-9814) and provide event ID SURMODICS.

An audio replay of the conference call will be available beginning at 11:00 a.m. CT today, until 11:00 a.m. CT on Wednesday, November 22, and can be accessed by dialing 877-660-6853 (international callers may dial 201-612-7415) and entering access ID 13741954. In addition, the webcast and transcript will be archived on the company’s website following the call.

About Surmodics, Inc.

Surmodics, Inc. is a leading provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. Surmodics also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. This key growth strategy leverages the combination of the company’s expertise in proprietary surface modification and drug-delivery coating technologies, along with its device design, development and manufacturing capabilities. The company’s mission is to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. For more information, visit www.surmodics.com. The content of Surmodics’ website is not part of this press release or part of any filings that the company makes with the SEC.

Safe Harbor for Forward-looking Statements

This press release, and disclosures related to it, contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical or current facts, including statements regarding: future success; our foundation for growth and commitment to executing on our growth strategy efficiently to maintain a healthy balance sheet while positioning Surmodics for strong, sustainable, long-term growth and value creation; our ability to make future draws on our term loan facility; our ability to access dept capital; expectations about Abbott’s launch and initial commercialization of the SurVeil DCB; our expected fulfillment of Abbott’s initial stocking order of the SurVeil DCB products; the potential of the SurVeil DCB to be a growth catalyst and the market opportunity for the product; our belief that Abbott is well-positioned to take advantage of attractive market dynamics for the SurVeil DCB and our commitment to supporting it; expectations about the three-year results of the TRANSCEND pivotal trial being presented; our future prospects; our product pipeline; continuing the sales momentum of our Sublime radial and Pounce arterial thrombectomy platforms in fiscal 2024; our expectations regarding our Preside coating technology; our expectations related to additional limited market evaluation cases for our Pounce venous thrombectomy system and its commercial launch; our fiscal 2024 financial guidance and related assumptions, including assumptions in our revenue guidance provided for modeling purposes, expected changes in revenues, expected license fee revenue related to the SurVeil DCB, expected product gross margins for fiscal 2024 and factors that we expect to impact product gross margins, expected operating expenses, expected interest expense, and expected tax expense; expected revenue for the first quarter of our fiscal 2024; our expected cash balance at the end of fiscal 2024 and expected uses of cash; expectations related to further borrowings during fiscal 2024 under our credit agreement; our fiscal 2024 strategic objectives; and further and future growth and value creation in the years to come, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and important factors could cause actual results to differ materially from those anticipated, including, without limitation: (1) our ability to successfully develop and commercialize our SurVeil DCB (including realization of the full potential benefits of our agreement with Abbott), Avess™ DCB, Sundance DCB, and other proprietary products; (2) our reliance on third parties (including our customers and licensees) and their failure to successfully develop, obtain regulatory approval for, market, and sell products incorporating our technologies; (3) possible adverse market conditions and possible adverse impacts on our cash flows; (4) our ability to successfully and profitably commercialize our vascular intervention products; (5) supply chain constraints; (6) whether our operating expenses are effective in generating profitable revenues; (7) disruptions to our business from our plan to reduce our use of cash announced in the second quarter of fiscal 2023, the failure of such plan to achieve its objectives, or cost and expenses associated with such plan; and (8) the factors identified under “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2022 and subsequent SEC filings. These reports are available in the Investors section of our website at https://surmodics.gcs-web.com and at the SEC website at www.sec.gov. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them in light of new information or future events.

Use of Non-GAAP Financial Information

In addition to reporting financial results in accordance with U.S. generally accepted accounting principles, or GAAP, Surmodics is reporting non-GAAP financial results including total revenue excluding SurVeil DCB license fee revenue, Medical Device revenue excluding SurVeil DCB license fee revenue, EBITDA and Adjusted EBITDA, non-GAAP operating (loss) income, non-GAAP operating (loss) income percentage, non-GAAP (loss) income before income taxes, non-GAAP net income (loss), and non-GAAP income (loss) per diluted share. We believe that these non-GAAP measures, when read in conjunction with the company’s GAAP financial statements, provide meaningful insight into our operating performance excluding certain event-specific matters, and provide an alternative perspective of our results of operations. We use non-GAAP measures, including those set forth in this release, to assess our operating performance and to determine payouts under our executive compensation programs. We also are providing guidance on a range of non-GAAP revenue and loss per diluted share for fiscal 2024. We believe that presentation of certain non-GAAP measures allows investors to review our results of operations from the same perspective as management and our board of directors and facilitates comparisons of our current results of operations. The method we use to produce non-GAAP results is not in accordance with GAAP and may differ from the methods used by other companies. Non-GAAP results should not be regarded as a substitute for corresponding GAAP measures but instead should be utilized as a supplemental measure of operating performance in evaluating our business. Non-GAAP measures do have limitations in that they do not reflect certain items that may have a material impact on our reported financial results. As such, these non-GAAP measures should be viewed in conjunction with both our financial statements prepared in accordance with GAAP and the reconciliation of the supplemental non-GAAP financial measures to the comparable GAAP results provided for the specific periods presented, which are attached to this release.

Surmodics, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(in thousands, except per share data)

(Unaudited)

 

 

Three Months Ended September 30,

 

Fiscal Year Ended September 30,

 

2023

 

2022

 

2023

 

2022

Revenue:

 

 

 

 

 

 

 

 

 

 

 

Product sales

$

15,363

 

 

$

14,394

 

 

$

60,614

 

 

$

54,621

 

Royalties and license fees

 

10,051

 

 

 

9,510

 

 

 

62,398

 

 

 

36,248

 

Research, development and other

 

2,556

 

 

 

2,084

 

 

 

9,572

 

 

 

9,082

 

Total revenue

 

27,970

 

 

 

25,988

 

 

 

132,584

 

 

 

99,951

 

Operating costs and expenses:

 

 

 

 

 

 

 

 

 

 

 

Product costs

 

7,039

 

 

 

5,597

 

 

 

24,965

 

 

 

20,342

 

Research and development

 

9,696

 

 

 

12,259

 

 

 

46,595

 

 

 

50,609

 

Selling, general and administrative

 

12,807

 

 

 

13,779

 

 

 

51,884

 

 

 

46,935

 

Acquired intangible asset amortization

 

878

 

 

 

966

 

 

 

3,537

 

 

 

4,150

 

Restructuring expense

 

 

 

 

 

 

 

1,282

 

 

 

 

Contingent consideration (gain) expense

 

 

 

 

 

 

 

(829

)

 

 

12

 

Total operating costs and expenses

 

30,420

 

 

 

32,601

 

 

 

127,434

 

 

 

122,048

 

Operating (loss) income

 

(2,450

)

 

 

(6,613

)

 

 

5,150

 

 

 

(22,097

)

Other expense, net

 

(339

)

 

 

(179

)

 

 

(2,663

)

 

 

(396

)

(Loss) income before income taxes

 

(2,789

)

 

 

(6,792

)

 

 

2,487

 

 

 

(22,493

)

Income tax benefit (expense)

 

9,483

 

 

 

(7,936

)

 

 

(4,023

)

 

 

(4,781

)

Net income (loss)

$

6,694

 

 

$

(14,728

)

 

$

(1,536

)

 

$

(27,274

)

 

 

 

 

 

 

 

 

 

 

 

 

Basic income (loss) per share

$

0.48

 

 

$

(1.06

)

 

$

(0.11

)

 

$

(1.96

)

Diluted income (loss) per share

$

0.47

 

 

$

(1.06

)

 

$

(0.11

)

 

$

(1.96

)

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of shares outstanding:

 

 

 

 

 

 

 

 

 

 

 

Basic

 

14,063

 

 

 

13,944

 

 

 

14,031

 

 

 

13,916

 

Diluted

 

14,152

 

 

 

13,944

 

 

 

14,031

 

 

 

13,916

 

 

Surmodics, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(in thousands)

 

 

September 30,

 

2023

 

2022

Assets

(Unaudited)

 

 

(See Note)

 

Current Assets:

 

 

 

 

 

Cash and cash equivalents

$

41,419

 

 

$

18,998

 

Available-for-sale securities

 

3,933

 

 

 

 

Accounts receivable, net

 

10,850

 

 

 

10,452

 

Contract assets — royalties and license fees

 

7,796

 

 

 

7,116

 

Inventories, net

 

14,839

 

 

 

11,819

 

Prepaids and other

 

7,854

 

 

 

9,202

 

Total Current Assets

 

86,691

 

 

 

57,587

 

Property and equipment, net

 

26,026

 

 

 

27,148

 

Intangible assets, net

 

26,206

 

 

 

28,145

 

Goodwill

 

42,946

 

 

 

40,710

 

Other assets

 

3,864

 

 

 

4,769

 

Total Assets

$

185,733

 

 

$

158,359

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

Current Liabilities:

 

 

 

 

 

Short-term borrowings

 

 

 

 

10,000

 

Deferred revenue

 

4,378

 

 

 

4,160

 

Other current liabilities

 

19,576

 

 

 

17,919

 

Total Current Liabilities

 

23,954

 

 

 

32,079

 

Long-term debt, net

 

29,405

 

 

 

 

Deferred revenue

 

2,400

 

 

 

5,088

 

Other long-term liabilities

 

10,064

 

 

 

12,800

 

Total Liabilities

 

65,823

 

 

 

49,967

 

Total Stockholders’ Equity

 

119,910

 

 

 

108,392

 

Total Liabilities and Stockholders’ Equity

$

185,733

 

 

$

158,359

 

 

 

 

 

 

 

Note: Derived from audited financial statements as of the date indicated.

 

 

Surmodics, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(in thousands)

(Unaudited)

 

 

Fiscal Year Ended September 30,

 

2023

 

2022

Operating Activities:

 

 

 

 

 

Net loss

$

(1,536

)

 

$

(27,274

)

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:

 

 

 

 

 

Depreciation and amortization

 

8,522

 

 

 

9,142

 

Stock-based compensation

 

7,605

 

 

 

7,057

 

Deferred taxes

 

(181

)

 

 

5,268

 

Other

 

340

 

 

 

860

 

Change in operating assets and liabilities:

 

 

 

 

 

Accounts receivable and contract assets

 

(977

)

 

 

(1,522

)

Inventories

 

(3,020

)

 

 

(5,060

)

Prepaids and other

 

 

 

 

(665

)

Accounts payable

 

(183

)

 

 

1,608

 

Accrued liabilities

 

(1,024

)

 

 

132

 

Income taxes

 

3,438

 

 

 

(1,069

)

Deferred revenue

 

(2,470

)

 

 

(5,700

)

Net cash provided by (used in) operating activities

 

10,514

 

 

 

(17,223

)

Investing Activities:

 

 

 

 

 

Purchases of property and equipment

 

(2,918

)

 

 

(3,370

)

Purchases of available-for-sale securities

 

(3,904

)

 

 

 

Maturities of available-for-sale securities

 

 

 

 

9,600

 

Net cash (used in) provided by investing activities

 

(6,822

)

 

 

6,230

 

Financing Activities:

 

 

 

 

 

Payments on short-term borrowings

 

(10,000

)

 

 

 

Proceeds from issuance of long-term debt

 

29,664

 

 

 

 

Payment of debt issuance costs

 

(614

)

 

 

 

Issuance of common stock

 

1,252

 

 

 

1,246

 

Payments for taxes related to net share settlement of equity awards

 

(918

)

 

 

(1,121

)

Payments for acquisition of in-process research and development

 

(978

)

 

 

(500

)

Net cash provided by (used in) financing activities

 

18,406

 

 

 

(375

)

Effect of exchange rate changes on cash

 

323

 

 

 

(787

)

Net change in cash and cash equivalents

 

22,421

 

 

 

(12,155

)

Cash and Cash Equivalents:

 

 

 

 

 

Beginning of year

 

18,998

 

 

 

31,153

 

End of year

$

41,419

 

 

$

18,998

 

 

Surmodics, Inc. and Subsidiaries

Supplemental Revenue Information

(in thousands)

(Unaudited)

 

 

Three Months Ended

 

 

 

 

Fiscal 2023 vs. 2022

 

Dec 31,

 

Mar 31,

 

Jun 30,

 

Sep 30,

 

Fiscal

 

Increase (Decrease)

 

2022

 

2023

 

2023

 

2023

 

2023

 

$

 

%

Medical Device Revenue

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product sales

$

8,380

 

 

$

7,914

 

 

$

9,299

 

 

$

8,533

 

 

$

34,126

 

 

$

6,196

 

 

 

22

%

Royalties & license fees – performance coatings

 

7,469

 

 

 

8,098

 

 

 

8,286

 

 

 

8,959

 

 

 

32,812

 

 

 

2,265

 

 

 

7

%

License fees – SurVeil DCB(1)

 

1,296

 

 

 

1,331

 

 

 

25,867

 

 

 

1,092

 

 

 

29,586

 

 

 

23,885

 

 

 

419

%

R&D and other

 

1,873

 

 

 

2,364

 

 

 

2,562

 

 

 

2,460

 

 

 

9,259

 

 

 

1,048

 

 

 

13

%

Medical Device revenue

 

19,018

 

 

 

19,707

 

 

 

46,014

 

 

 

21,044

 

 

 

105,783

 

 

 

33,394

 

 

 

46

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

In Vitro Diagnostics Revenue

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product sales

 

5,854

 

 

 

7,436

 

 

 

6,368

 

 

 

6,830

 

 

 

26,488

 

 

 

(203

)

 

 

(1

)%

R&D and other

 

61

 

 

 

55

 

 

 

101

 

 

 

96

 

 

 

313

 

 

 

(558

)

 

 

(64

)%

In Vitro Diagnostics revenue

 

5,915

 

 

 

7,491

 

 

 

6,469

 

 

 

6,926

 

 

 

26,801

 

 

 

(761

)

 

 

(3

)%

Total Revenue

$

24,933

 

 

$

27,198

 

 

$

52,483

 

 

$

27,970

 

 

$

132,584

 

 

$

32,633

 

 

 

33

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Medical Device revenue, excluding

SurVeil DCB license fees
(1)

$

17,722

 

 

$

18,376

 

 

$

20,147

 

 

$

19,952

 

 

$

76,197

 

 

$

9,509

 

 

 

14

%

Total Revenue, excluding

SurVeil DCB license fees
(1)

$

23,637

 

 

$

25,867

 

 

$

26,616

 

 

$

26,878

 

 

$

102,998

 

 

$

8,748

 

 

 

9

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

 

 

 

 

 

 

 

Dec 31,

 

Mar 31,

 

Jun 30,

 

Sep 30,

 

Fiscal

 

 

 

 

 

 

 

2021

 

2022

 

2022

 

2022

 

2022

 

 

 

 

 

 

Medical Device Revenue

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product sales

$

6,788

 

 

$

6,441

 

 

$

6,741

 

 

$

7,960

 

 

$

27,930

 

 

 

 

 

 

 

Royalties & license fees – performance coatings

 

6,937

 

 

 

8,369

 

 

 

7,827

 

 

 

7,414

 

 

 

30,547

 

 

 

 

 

 

 

License fees – SurVeil DCB(1)

 

1,162

 

 

 

1,475

 

 

 

968

 

 

 

2,096

 

 

 

5,701

 

 

 

 

 

 

 

R&D and other

 

2,021

 

 

 

2,168

 

 

 

1,992

 

 

 

2,030

 

 

 

8,211

 

 

 

 

 

 

 

Medical Device revenue

 

16,908

 

 

 

18,453

 

 

 

17,528

 

 

 

19,500

 

 

 

72,389

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

In Vitro Diagnostics Revenue

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product sales

 

5,556

 

 

 

7,523

 

 

 

7,178

 

 

 

6,434

 

 

 

26,691

 

 

 

 

 

 

 

R&D and other

 

539

 

 

 

130

 

 

 

148

 

 

 

54

 

 

 

871

 

 

 

 

 

 

 

In Vitro Diagnostics revenue

 

6,095

 

 

 

7,653

 

 

 

7,326

 

 

 

6,488

 

 

 

27,562

 

 

 

 

 

 

 

Total Revenue

$

23,003

 

 

$

26,106

 

 

$

24,854

 

 

$

25,988

 

 

$

99,951

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Medical Device revenue, excluding

SurVeil DCB license fees
(1)

$

15,746

 

 

$

16,978

 

 

$

16,560

 

 

$

17,404

 

 

$

66,688

 

 

 

 

 

 

 

Total Revenue, excluding

SurVeil DCB license fees
(1)

$

21,841

 

 

$

24,631

 

 

$

23,886

 

 

$

23,892

 

 

$

94,250

 

 

 

 

 

 

 

 

Surmodics, Inc. and Subsidiaries

Supplemental Segment Information

(in thousands)

(Unaudited)

 

 

Three Months Ended September 30,

 

Fiscal Year Ended September 30,

 

2023

 

2022

 

2023

 

2022

Operating (Loss) Income:

 

 

 

 

 

 

 

 

 

 

 

Medical Device

$

(2,399

)

 

$

(6,211

)

 

$

5,084

 

 

$

(22,923

)

In Vitro Diagnostics

 

3,187

 

 

 

2,811

 

 

 

12,637

 

 

 

13,073

 

Total segment operating income (loss)

 

788

 

 

 

(3,400

)

 

 

17,721

 

 

 

(9,850

)

Corporate

 

(3,238

)

 

 

(3,213

)

 

 

(12,571

)

 

 

(12,247

)

Total (Loss) Income from Operations

$

(2,450

)

 

$

(6,613

)

 

$

5,150

 

 

$

(22,097

)

 

Surmodics, Inc. and Subsidiaries

Reconciliation of GAAP Measures to Non-GAAP Amounts

Schedule of EBITDA and Adjusted EBITDA

(in thousands)

(Unaudited)

 

 

Three Months Ended September 30,

 

Fiscal Year Ended September 30,

 

2023

 

2022

 

2023

 

2022

Net Income (Loss)

$

6,694

 

 

$

(14,728

)

 

$

(1,536

)

 

$

(27,274

)

Income tax (benefit) expense

 

(9,483

)

 

 

7,936

 

 

 

4,023

 

 

 

4,781

 

Depreciation and amortization

 

2,157

 

 

 

2,240

 

 

 

8,522

 

 

 

9,142

 

Interest expense, net

 

895

 

 

 

188

 

 

 

3,489

 

 

 

598

 

Investment income, net

 

(546

)

 

 

(26

)

 

 

(1,077

)

 

 

(99

)

EBITDA

 

(283

)

 

 

(4,390

)

 

 

13,421

 

 

 

(12,852

)

 

 

 

 

 

 

 

 

 

 

 

 

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation expense

 

1,943

 

 

 

1,859

 

 

 

7,605

 

 

 

7,057

 

Restructuring expense(2)

 

 

 

 

 

 

 

1,282

 

 

 

 

Contingent consideration fair value adjustment(3)

 

 

 

 

 

 

 

(829

)

 

 

 

Adjusted EBITDA

$

1,660

 

 

$

(2,531

)

 

$

21,479

 

 

$

(5,795

)

 

Surmodics, Inc. and Subsidiaries

Net Income (Loss) and Diluted EPS GAAP to Non-GAAP Reconciliation

(in thousands, except per share data)

(Unaudited)

 

 

For the Three Months Ended September 30, 2023

 

Operating Loss

 

Loss Before

Income Taxes

 

Net Income(6)

 

Diluted EPS

GAAP

$

(2,450

)

 

 

(8.8

)%

 

$

(2,789

)

 

$

6,694

 

 

$

0.47

 

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of acquired intangible assets(4)

 

878

 

 

 

3.2

%

 

 

878

 

 

 

812

 

 

 

0.06

 

Non-GAAP

$

(1,572

)

 

 

(5.6

)%

 

$

(1,911

)

 

$

7,506

 

 

$

0.53

 

Diluted weighted average shares

outstanding(7)

 

 

 

 

 

 

 

 

 

 

 

 

 

14,152

 

 
 

 

For the Three Months Ended September 30, 2022

 

 

Operating Loss

 

Loss Before

Income Taxes

 

Net Loss(6)

 

Diluted EPS

GAAP

$

(6,613

)

 

 

(25.4

)%

 

$

(6,792

)

 

$

(14,728

)

 

$

(1.06

)

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of acquired intangible assets(4)

 

966

 

 

 

3.7

%

 

 

966

 

 

 

906

 

 

 

0.07

 

Tax expense from full valuation allowance

against U.S. deferred tax assets(5)

 

 

 

 

 

 

 

 

 

 

10,151

 

 

 

0.73

 

Non-GAAP

$

(5,647

)

 

 

(21.7

)%

 

$

(5,826

)

 

$

(3,671

)

 

$

(0.26

)

Diluted weighted average shares

outstanding(7)

 

 

 

 

 

 

 

 

 

 

 

 

 

13,944

 

 
 

 

Fiscal Year Ended September 30, 2023

 

 

Operating Income

 

Income Before

Income Taxes

 

Net (Loss)

Income(6)

 

Diluted EPS

GAAP

$

5,150

 

 

 

3.9

%

 

$

2,487

 

 

$

(1,536

)

 

$

(0.11

)

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of acquired intangible assets(4)

 

3,537

 

 

 

2.6

%

 

 

3,537

 

 

 

3,279

 

 

 

0.24

 

Restructuring expense(2)

 

1,282

 

 

 

1.0

%

 

 

1,282

 

 

 

1,282

 

 

 

0.09

 

Contingent consideration fair value

adjustment(3)

 

(829

)

 

 

(0.6

)%

 

 

(829

)

 

 

(829

)

 

 

(0.06

)

Non-GAAP

$

9,140

 

 

 

6.9

%

 

$

6,477

 

 

$

2,196

 

 

$

0.16

 

Diluted weighted average shares

outstanding(7)

 

 

 

 

 

 

 

 

 

 

 

 

 

14,071

 

 
 

 

Fiscal Year Ended September 30, 2022

 

 

Operating Loss

 

Loss Before

Income Taxes

 

Net Loss(6)

 

Diluted EPS

GAAP

$

(22,097

)

 

 

(22.1

)%

 

$

(22,493

)

 

$

(27,274

)

 

$

(1.96

)

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of acquired intangible assets(4)

 

4,150

 

 

 

4.1

%

 

 

4,150

 

 

 

3,888

 

 

 

0.28

 

Tax expense from full valuation allowance

against U.S. deferred tax assets(5)

 

 

 

 

 

 

 

 

 

 

10,151

 

 

 

0.73

 

Non-GAAP

$

(17,947

)

 

 

(18.0

)%

 

$

(18,343

)

 

$

(13,235

)

 

$

(0.95

)

Diluted weighted average shares

outstanding(7)

 

 

 

 

 

 

 

 

 

 

 

 

 

13,916

 

 

Surmodics, Inc. and Subsidiaries

Guidance Reconciliation: Estimated Revenue

For the Fiscal Year Ending September 30, 2024

(in millions)

(Unaudited)

 

 

Fiscal 2024 Full-Year Estimate

 

Increase (Decrease)

 

 

 

 

Low

 

High

 

Low

 

High

 

Fiscal 2023

Total Revenue

$

116

 

 

$

121

 

 

 

(13

)%

 

 

(9

)%

 

$

133

 

License fees – SurVeil DCB(1)

 

(4

)

 

 

(4

)

 

 

(86

)%

 

 

(86

)%

 

 

(30

)

Total Revenue, excluding SurVeil DCB license fees(1)

$

112

 

 

$

117

 

 

 

9

%

 

 

14

%

 

$

103

 

 

Surmodics, Inc. and Subsidiaries

Guidance Reconciliation: Estimated Non-GAAP Diluted EPS

For the Fiscal Year Ending September 30, 2024

(shares in thousands)

(Unaudited)

 

 

Fiscal 2024 Full-Year Estimate

 

Low

 

High

GAAP Diluted EPS

$

(1.55

)

 

$

(1.20

)

Amortization of acquired intangibles per diluted share(4)

 

0.23

 

 

 

0.23

 

Non-GAAP Diluted EPS

$

(1.32

)

 

$

(0.97

)

Diluted weighted average shares outstanding

 

14,150

 

 

 

 

 

(1)

SurVeil DCB license fee revenue represents revenue recognition on milestone payments received under the company’s Development and Distribution Agreement with Abbott (“Abbott Agreement”).

(2)

Restructuring expense consists of severance and related costs specifically associated with a workforce restructuring implemented in the second quarter of fiscal 2023.

(3)

Represents accounting adjustments to state acquisition-related contingent consideration liabilities at their estimated fair value as of the period end date, including adjustments to the liabilities’ fair values related to changes in the timing and/or probability of achieving milestones and accretion expense for the passage of time.

(4)

Represents amortization of business acquisition-related intangible assets and associated tax impact. A significant portion of the business acquisition-related amortization is not tax deductible.

(5)

Represents the non-cash charge to income tax expense that resulted from the establishment of a full valuation allowance against U.S. net deferred tax assets in the fourth quarter of fiscal 2022. A valuation allowance is required to be recognized against deferred tax assets if, based on the available evidence, it is more likely than not (defined as a likelihood of more than 50%) that all or a portion of such assets will not be realized. The relevant guidance weighs available evidence such as historical cumulative taxable losses more heavily than future profitability. The valuation allowance has no impact on the availability of U.S. net deferred tax assets to offset future tax liabilities.

(6)

Net income (loss) includes the effect of the above adjustments on income tax benefit (expense), taking into account deferred taxes net of valuation allowances, as well as non-deductible items. Income tax impacts were estimated using the applicable statutory rate (21% in the U.S. and 12.5% in Ireland).

(7)

Diluted weighted average shares outstanding used in the calculation of EPS was the same for GAAP EPS and Non-GAAP EPS for the three months ended September 30, 2023 and 2022 and the fiscal year ended September 30, 2022. For the fiscal year ended September 30, 2023, diluted weighted average shares outstanding used in the calculation of EPS was 14,031 for GAAP EPS due to the net loss in the period, and 14,071 for Non-GAAP EPS corresponding to the Non-GAAP net income in the period.

 

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.